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Pharmacologic Modulation of Experimental 
Postischemic Hepatic Function 
SHERYL J. ONTEll. M.D.:t LEONARD MAKOWKA, M.D., PH.D." JONATHAN TRAGER, B.A.: 
VINCENZO MAZZAFERRO, M.D." PETER OVE, PH.D.,t and THOMAS E. STARZl, M.D., PH.D: 
The present study e\aluated and compared the effects of SRI 
63-441. a potent platelet actinting factor antagonist. superoxide 
dismutase (SOD). an oxygen free radical sca\enger. and ibu-
profen. a cycloox~Dgenase inhibitor on hepatic function after 90 
minutes of warm ischemia. After warm ischemia. Ihers were 
hancsted and undenlent 90 minutes of w·arm. oxygenated. san-
guinous perfusion on an isolated Iher perfusion apparatus. Pre-
treatment of donor animals with 20 mg/kg intra\'enous (I.V.) 
SRI 63-4.-. 5 minutes before induction of total hepatic ischemia 
resulted in significantly increased bile production. a significant 
decrease in transaminase release. and a higher tissue adenosine 
triphosphate (A TP) content when compared w'ith ischemic non-
treated controls. SOD resulted in impro¥ed bile production and 
decreased transaminase liberation only when present in the per-
fusate at the time of in pitro reperfusion. Ibuprofen did not im-
pron postischemic hepatic function in this model. Electron mi-
croscopy re¥ealed patchy hepatocellular \'acuolization with an 
intact sinusoidal endothelium in all ischemic li~ersK lIowe¥er. 
the degree of damage was less se\'ere in the lhers from those 
rats pretreated with 20 mg/kg SRI 63-441. This study demon-
~trates that SRI 63 ..... 1 pretreatment significantly reduces he-
patic warm ischemic injury. and in the present model. appears 
superior to two other agents that han been ad~anced in the 
treatment of ischemic injury. The use of such agents singly or 
in combinations hue important implications as regards gaining 
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a better understanding of the basic mechanisms in organ isch-
emia, and moreo¥er. for therapeutic applications in organ Isch-
emia and preserntion. 
O RGAN INJURY after ischemia and reperfusion remains one of the most formidable limiting 
factors in the field of transplantation. The isch-
emia suffered during the process of transplantation is 
comprised of both a wann and cold component. There is 
emerging evidence suggesting that warm and cold isch-
emia result in two different types of injury. I The com-
plexity of the interactions between the various mediators,'. 
as well as the redundancy and resiliency of the various~ 
cascades. prompted us to investigate potential therapeutie::K~ 
agents for organ ischemia that are thought to exen their' 
effects by different mechanisms. In the present study, we 
have evaluated the effect of three pharmacologic candi-
dates on hepatic function after warm ischemic injury using 
the isolated perfused rat liver (lPRL).2 
The mediators and cascades involved in the inflam-
matory response to ischemia/reperfusion injury are quite 
complex and interrelated. They include the generation of 
oxygen· free radicals. arachidonic acid metabolites. and 
platelet activating factor (PAF). P AF is a key inflammatory 
mediator elaborated by a variety of cell types. including 
platelets. neutrophils. and the endothelium, and is inti-
mately involved in the microcirculatory response to non-
immunologic and immunologic inflammatory stimuli.3-8 
Many of the pathophysiologic responses and the micro-
circulatory failure that result from PAF release mimic the 
progression of responses observed after ischemia/reper-
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fusion injury, SRI 63-441 (Sandoz Pharmaceuticals. North 
Hanover, NJ) is a potent receptor antagonist ofPAF that 
can inhibit all of the known biological responses to PAF.9 
Thus. the availability of such an antagonist could give 
further insight into the basic mechanisms involved in the 
iscbemic process, and could have significant potential as 
a therapeutic agent for ischemic organ injury, 
Recently there has been much interest in the role of 
oxygen-free radicals in ischemia and reperfusion injury. 10 
Oxygen-free radicals have been implicated in ischemia/ 
reperfusion injury in both the liver and kidney, 11·14 In the 
present study, three different protocols using superoxide 
dismutase (SOD) (Pharmacia Co" Uppsaia, Sweden), an 
oxygen-free radical scavenger, were evaluated, as well as 
a combined protocol using SOD and SRI 63-441, 
The nonsteroidal anti-inflammatory agent and cy-
clooxygenase inhibitor, ibuprofen (Upjohn Company. 
Kalamazoo. MI).AQS has been reported to have the ability 
to salvage ischemic myocardium during infarction in the 
dog. i $ Its protective mechanism may be via stabilization 
of cellular membranes and prevention of thromboxane 
release. 16 Ibuprofen has also demonstrated a protective 
effect on bowel ischemia 17 and improves survival and 
neurologic outcome after resuscitation from cardiac ar-
rest. 18 This protective effect of ibuprofen was further eval-
uated in these studies of ischemia/reperfusion injury in 
the liver. 
Of the three agents investigated. SRI 63-441 at a dose 
of 20 mg,lkg administered intravenously produced the 
most significant improvement in postischemic hepatic 
function as determined by the parameters measured. His-
tologic evaluation of the SRI 63-441 pretreated Ii vers was 
c~ed out using light and electron microscopy, and has 
gIven funher insight into the mechanism of warm isch-
i!mic liver injury, specifically how it compares with cold 
ischemic liver injury. 
Materials and Methods 
Animals 
Male Lewis rats (Charles River Breed Laboratories 
Wilmington, MA) weighing 225-300 g were used as live; 
donors and male Lewis rat retired breeders were used as 
blOOd donors in these experiments. Animals were accli-
matized for I week before experimentation and housed 
-In a standard animal facility at the University of Pitts-
bUrgh. Animals were fed standard rat chow and water ad 
libitum. Guidelines for the care and use oflaboratory an-
Imals of the University of Pittsburgh were followed. 
Operative Procedure 
Inhalational anesthesia was administered and main-
tained with methoxyflurane. The abdomen was entered 
through a transverse incision. All animals received 300 
units of heparin intravenously 5 minutes before cannu-
lation of the bile duct and induction of total hepatic isch-
emia. Both the hepatic artery and portal vein were ligated. 
At the time of harvest, the liver was flushed via the portal 
vein with 60 cc of cold (4 C) heparinized lactated Ringer's 
solution from a height of 20 cm immediately after venting 
the vena cava. The portal vein was cannulated using a 
blunted 18 gauge needle. After 90 minutes of total in situ 
ischemia. the liver was harvested and placed on the per-
fusion apparatus. 
Isolated perfusion 
The perfusion apparatus was a recirculating system 
consisting of a pulsatile pump, "Hamilton Lung" oxy-
genator, debubbler/reservoir, effluent collecting basin. 
blood infusion filter, platelet trap, and in-line thermom-
eter.2.19.20 The temperature within the apparatus was 
maintained at 37 C with a circulating water bath. The 
liver was perfused via the portal vein only from a height 
of 18 cm.21 The rate of flow through the liver was regulated 
by the resistance of the intrahepatic microvasculature and 
varied between 10 and 20 cc/minute. Oxygenation was 
maintained using a 95% oxygen/5% carbon dioxide mix-
ture. resulting in a p02 of approximately 500 torr. 
Blood was obtained by aortic puncture after heparin-
izing both the blood donor and the syringe. The perfusate 
consisted of a dilute sanguinous solution prepared from 
two parts by volume of heparinized fresh whole rat blood 
and I part Krebs bicarbonate buffer.22 The resulting he-
matocrit was approximately 25%.23 The pH of the per-
fusate was maintained at approximately 7.4 with the ad-
dition of sodium bicarbonate. as necessary. Blood gases 
were checked before placing the liver on the circuit and 
periodically thereafter. All livers were perfused for a period 
of 90 minutes. 
Experimental Protocol 
The experimental groups are described in Table I. All 
livers in all groups underwent 90 minutes of warm. san-
guinous. oxygenated perfusion. 
Platelet Activating Factor Antagonist 
SRI 63-441. a PAF receptor antagonist. was supplied 
by Dr. Robert Saunders of San dOl Pharmaceuticals. North 
Hanover. New Jersey. The pharmacologic activity and 
physicochemical propenies of this specific compound 
have been described previously.9 It was supplied in a pow-
dered form and a IS-mg/ml solution was prepared daily 
in 0.9% sodium chloride. The solution was warmed to 37 
C to ensure that the SRI 63-441 was completely solubilized 
before injection. The agent was administered intrave-
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TABLE I. Experzmental Groups 
Group No. of Patients Ischemia Agent 
no 
2 9 yes 
8 no SRI 63-441 
4 9 yes SRI 63·441 
5 3 yes SRI 63-441 
6 4 yes SOD 
7 4 yes SOD 
8 4 yes SOD 
9 6 yes SRI 63-441 
SOD 
10 yes Ibuprofen 
11 no Ibuprofen 
• 8 mg;kg of SOD was added to the perfusate just before placing the 
liver on the perfusion apparatus (0 min.). 5 minutes after the liver was 
placed on the perfusion apparatus. and 10 minutes af\er the liver was 
nously at a dose of 20 mg/kg and 10 mg/kg 5 minutes 
before the induction of total hepatic ischemia. 
Superonde dismutase 
Dosage 
20 mg/kg 
20 mg/'Kg 
10 mg;kg 
12 mg/kg 
8 mg/kg 
12 mg/kg 
12 mg/kg 
12 mg/'Kg 
12 mg/kg 
8mg/kg 
20 mg/'Kg 
6.5 mg/kg 
6.5 mg/kg 
12 mg/kg 
1.8 mg 
12 mg/kg 
12 mg/kg 
1.8 mg 
12 mg/kg 
-Route Time Treated 
-
LV. At time of heparinizatioa 
LV. Attime of heparinizatioa 
I. V. At time of heparinizatioll 
fl ush At ti me of harvest 
perfusate at 0, S, 10 nUll 
perfusion- • 
LV. At time of heparinizatioa 
flush at time of harvest 
I. V. A t time of heparinizati01l 
flush at time of harvest 
perfusate at 0, S, 10 mill. 
perfusion-
I. V. At time of heparinizatioll 
fl ush at time of harvest 
perfusate at 0 min. 
perfusiont 
LV. 1 hour before surgery 
flush at time of harvest 
perf usage at 0 min. 
perfusiont 
I. V. 1 hour before surgery 
flush at time of harvest 
perfusate at 0 min. 
perfusiont 
placed on the perfusion apparatus. for a total dose of 24 mg/kg added. 
t Zero minutes perfusion IS just before placing the liver on the petfusioa 
Jpparatus. 
aminase (SGPT), and glucose were measured using the 
Technicon RA 500 (Technicon Instruments. Tarrytown, 
:-N) before placing the liver on the perfusion apparatus. 
Liver function during perfusion was determined by mea-
suring bile production. SGOT, SGPT, and glucose levels 
in the perfusate every 30 minutes. At the completion of 
the 90-minute perfusion period, tissue was immediately 
freeze-clamped in liquid nitrogen and adenosine triphos-
phate (A TP) content was determined biochemically.24 
Specimens were placed in formalin, embedded in paraffin, 
" 
The oxygen-free radical scavenger SOD was supplied by 
Pharmacia Company. (Upsala, Sweden). The bovine SOD 
was supplied in a powdered form and a 4-mgjml solution 
was prepared daily in 0.9% sodium chloride. SOD was given 
at the time of heparinization, added to the flush at the time 
of harve<it. or added to the perfusate (Table I). cut, and stained with hematoxylin and eosin and PAS for •. 
fbllpro/en 
The cyclooxygenase inhibitor ibuprofen was supplied 
by the Upjohn Company (Kalamazoo. Michigan). It was 
supplied as a sterile 50-mg/ml solution and. for experi-
mentation. was diluted to a 10-mg/ml solution with 0.9% 
sodium chloride daily. The animals were pretreated \\ith 
12-mg;kg ibuprofen administered intravenouslv I hour 
before surgery) 7 as well as the addition of ibuprofen to 
the flush at harvest (1.8 mg), and 12 mg/kg was added to 
the perfusate (Table I). 
Assessment of Lirer Status 
Baseline perfusate levels of serum glutamic oxaloacetic 
transaminase (SGOT). serum glutamic pyruvic trans-
light microscopy. An additional three experiments were 
repeated per group for experimental Groups I, 2, and 4, 
and the livers were processed for electron microscopy. '. 
After 90 minutes of warm sanguinous perfusion, the 
livers were perfused· fixed via the portal vein with 20 cc 
of 2.0% glutaraldehyde in 0.125 M cacodylate buffer at a 
rate of 5-10 cc/minute, minced to I X 1 X I mm cubes 
and placed in 2.0% glutaraldehyde for 2 hoursK:~ The livers 
were postfixed in buffered 2.0% osmium tetroxide, de-
hydrated in ethanol and embedded in Epan 812. Blocks 
were cut using a Reichert microtome. Semi-thin sections 
were stained with toluidine blue for light microscopy. Ul-
tra-thin sections were collected on grids, stained with ura-
nyl acetate and lead citrate, and were observed using a 
Phillips 300 electron microscope (Phillips Electronic In-
struments. Mahwah, NJ).26 
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TABLE 2. Parameters 0/ Liver Functlon Evaluated 
Group Bile Production SGOT SGPT 
I x x x 
2 x x x 
3 x X X 
4 X X X 
5 X X X 
6 x X X 
7 x X X 
8 X X X 
9 X X X 
10 X X X 
II X X X 
Not all of the parameters described above were deter-
mined for all groups. Experimental groups and the vari-
ables measured for each group are listed in Table 2. 
Statistics 
All values were corrected to baseline by subtracting the 
values obtained before placing the liver on the perfusion 
apparatus from the subsequent measurements at 30, 60. 
and 90 minutes of perfusion. The statistical evaluation 
was carried out using an analysis of variance. When in-
dicated. the Student's t-test was performed. using the 
variances generated by the ANOVA.27 All values reported 
are expressed as a mean ± the standard error of the mean 
(SEM); p values of less than 0.05 were considered statis-
tically significant. 
Results 
Treatment with SRI 63-441 
There was a significant increase in bile production (p 
< 0.005) by those livers harvested from rats that were 
pretreated with 20 mg/kg of SRI 63-441 administered in-
travenously I Fig. I). Perfusate transaminase levels were 
significantly lower from the ischemic livers of animals 
pretreated with 20 mg/kg SRI 63-441 (p < 0.(01) (Fig. 
2). There was no significant difference in transaminase 
release by SRI 63-44 I-treated and untreated livers from 
animals that had not undergone ischemic injury. A TP 
levels were significantly higher in the ischemic livers pre-
treated with 20 mg/kg of SRI 63-441 when compared 
with untreated livers (p < 0.05) (Fig. 3). When compared 
with untreated livers. ischemic livers from rats that were 
. Pretreated with only 10 mg/kg of SRI 63-441 administered 
Intravenously did not demonstrate any improvement in 
tenos of bile production. transaminase release, or ATP 
':ontent (Figs. 1-3). There was a significant difference in 
bile production. transaminase release. and A TP levels in 
untreated livers when comparing the group that under-
Went 90 minutes of total warm ischemia with the group 
that did not undergo an ischemic period (Figs. 1-3) (p 
<0.001). 
Glucose ATP Morphology: LM EM 
x x x X 
x x x x 
X X X 
X X X X 
X X 
X X 
X 
X 
Treatment with SOD 
Results of bile production and transaminase release for 
Groups 6-8 are described in Table 3. Of the ischemic 
livers that were treated with the three SOD protocols, only 
the group that received SOD, 12 mg/kg in the flush at 
harvest and 8 mg/kg in the perfusate at 0, 5, and 10 min-
utes of perfusion (i.e .. Group 6), experienced a significant 
increase in bile production after 90 minutes of perfusion, 
as well as a significant decrease in tramaminase release 
when compared with ischemic controls (p < 0.02). The 
group of livers that underwent pretreatment with 12 mg! 
kg of SOD followed by 12 mg/kg of SOD in the flush at 
harvest, but did not have SOD added to the perfusate 
(i.e .• Group 7), had no significant improvement in bile 
production after 90 minutes of perfusion and did not differ 
significantly from ischemic controls in the degree of 
transaminase release. Those livers that were pretreated 
with 12 mg/kg SOD, flushed with 12 mg/kg of SOD and 
had 8mg/kg of SOD added to the reperfusate at O. 5, and 
10 minutes of perfusion (i.e .. Group 8). did not demon-
strate a significant increase in bile production after 90 
minutes of perfusion, but did release significantly less 
SGOT (p < 0.05) and SGPT (p < 0.(01) into the perfusate 
when compared ",;th untreated ischemic controls. 
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FIG. I. Bile production (SRI 63-441). Bile production by IschemiC livers 
was essenllally nil. Low dose SRI 63-441 (10 mg.tkg) did not result in 
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FIG. 2. Perfusate SGPT levels (SRI 63-44 [l. A significant reduction in 
SGPT liberation was exhibited only by those ischemic livers harvested 
from donors pretreated ... ith SRI 63-44 [ (20 mglkg) (p < 0.001). An 
almost identical pattern was seen wlIh SGOT release (not shown). 
Combined Treatment with SRJ63-44! and SOD 
Bile production was significantly increased by those 
livers from the group that underwent a combination of 
pretreatment with 20 mg,lkg of SRI 63-441 administered 
intravenously and received 6.5 mg/kg SOD in the flush 
at harvest and 6.5 mg/kg SOD in the perfusate (p < 0.(01) 
when compared ..... ith ischemic controls (Fig. 1). ATP 
content was significantly higher (p < 0.05) in those livers 
treated with SOD plus SRI 63-441 than that of ischemic 
controls (Fig. 3). However, there was no significant dif-
ference in the amount of transaminase release between 
livers treated with a combination of SOD and SRI 63-
441 and ischemic controls (Fig. 2). 
Treatment with Ibuprofen 
The ischemic livers that were pretreated with 12 mg,l 
kg ibuprofen. flushed with 1.8 mg ibuprofen. and received 
12 mg/kg ibuprofen in the perfusate did not exhibit a 
IlllI '011"'_ 0 to Mil ""_ • 10.1111 'II 13-441 
~ ..... _ • lo.t/ll PI 13-441 [:J to .. IIC_ • 10 .. /11 '1113-441 
E:J " .. II,... C 90 l1li II ...... 10,,/11 'II 13-441 
• '01 II ... /11 ~ • I 5 .. lkl ... l1li111 
FIG. 3. Tissue A TP conlent. Ischemic livers manifested a significant re-
duction in A TP content when compared with nOnlschemlc livers (p 
< 0.00 Il. The liver tIssue A TP content was SIgnificantly higher in the 
group truled ... ilh SRI 63-441 (20 mg/kg) and the combined SODISRI 
63-441 treatment group (p < 0.05 l. 
significant dIfference in bile production or transanu_ 
release when compared ..... ith ischemic controls (FIgS. .-
and 5). There was also no significant difference in bile 
production after 90 minutes of perfusion. or in trans.. 
aminase release for ibuprofen-treated nonischemic livers 
and nonischemic controls (Figs. 4 and 5). 
There was no significant difference in perfusate gluCOSe 
levels between ischemic controls and any of the iscbelllic 
experimentally treated groups, or between nonischentic 
controls and any of the nonischemic treated groups." 
Therefore. glucose release does not appear to be a valid 
predictor of liver function in this model. 
Electron Jficroscopy 
All samples for electron microscopy were taken after 
the 90-minute perfusion period. Electron microscopy was 
done for Groups I, 2, and 4 only. Electron microscopy 
of the nonischemic control livers (Group I) revealed in-
tact. healthy-appearing hepatocytes as well as intact, 
well-preserved sinusoidal endothelial cells (Fig. 6A). The 
ischemic livers (Group 2) exhibited a patchy picture of 
hepatocellular damage (Fig. 6B). Vacuolated and pale. 
staining nonviable hepatocytes containing many disrupted 
mitochondria were found interspersed with viable hepa. 
tocytes. The sinusoidal endothelium remained intact when 
covering viable hepatocytes, but was disrupted in areas 
adjacent to nonviable hepatocytes (Fig. 7). Sections from 
ischemic livers that were harvested from donors pretreated 
with SRI 63-441 (20 mg/kg) (Group 4) demonstrated rel-
atively normal-appearing hepatocytes with few vacuoles 
and intact sinusoidal endothelium (Figure 60. The patchy 
distribution of injury combined with the small cross-sec-
tional area observed with electron microscopy introduces 
the possibility that the sections viewed were not represen· 
tative of the true morphologic picture. In fact. sections of. 
the ischemic nontreated livers could be found that man-; 
ifested relatively healthy-appearing hepatocytes. In order:! 
to obtain a better overview, paraffin embedded tissue was . 
cut and stained with hematoxylin and eosin and PAS for 
light microscopy. 
Light Microscopy 
The nonischemic control livers exhibited normal. 
healthy-appearing hepatocytes. PAS-stained sections were 
glycogen-laden (Fig. 8A). The ischemic livers contained 
large patches of pale-staining, nonviable hepatocytes and 
vacuolization interspersed with nonnal appearing bepa· 
tocytes. PAS-staining revealed large patchy areas of gly. 
cogen depletion (Fig. 8B). Ischemic livers from donors 
pretreated with SRI 163-441 (20 mg/kg) also contained 
some foci of pale-staining, nonviable hepatocytes and 
vacuolization. Although quantitative analysis was not 
carried out. the foci of injury in the SRI 63-441 pretreated 
--------------------~------~-----------·~--~~--~qD--~----~----~rr ..A&. 
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TABLE 3. The Effect 0/ SOD on Paramerers 0/ Hepallc Function 
Group' No. of Patients Min. Perfusion 
2 9 30 
60 
90 
6 4 30 
60 
90 
7 4 30 
70 
90 
8 4 30 
60 
90 
• See Table I for descriptions of groups. All values expressed X 
±SEM. 
t p of at least <0.05 when compared with corresponding values for 
untreated ischemiC controls (Group 2). There is no significant difference 
ischemic livers were generally smaller in size and less 
abundant than in the untreated ischemic livers. The pre-
treated ischemic livers were largely glycogen depleted, in 
fact, to a greater extent than even the untreated ischemic 
livers (Fig. 8C). Nonischemic livers from rats pretreated 
with 20 mg/kg SRI 63-441 had normal-appearing hepa-
tocytes, but also demonstrated patchy glycogen depletion 
(not shown). 
Discussion 
Ischemia/reperfusion injury appears to be integrally tied 
to the inflammatory response, resulting in microcircula-
tory failure followed by necrosis and cell death. The path-
ways implicated as causa.tive of the injury to the micro-
circulation that occurs in this process are mUltiple and 
complex. These highly interrelated and redundant cas-
cades involved in the mediation of ischemia/reperfusion 
injury make it highly likely that effective pharmacologic 
modulation of the injury, leading to prevention of both 
....... , ... lKi-KKK:i:i:f:ifKKKK~-KKK:KK~ __ 
I ... 
Bile (I'l/min/g) 
0.003 ± 0.003 
0.09 ± 0.03 
0.15 ± 0.04 
0.14 ± 0.11 
0.35 ± 0.14t 
0.37 ± O.llt 
0.23 ±0.12H 
0.19 ± 0.03 
0.17 ±0.03 
0.23 ± lKM9t~ 
0.17 ±0.06 
0.12 ±0.05 
between Groups 6, 7, and 8. 
SGOT 
946 ± 107 
1108 ± 143 
1237 ± 142 
366 ± 103t 
455 ± 122t 
603 ± 163t 
720 ± 186 
901 ± 185 
1095 ± 196 
478 ± 129t 
559 ± 1JOt 
740 ± 170t 
SGPT 
1066 ± 162 
1269 ± 132 
1349 ± 118 
383 ± 103t 
448 ± 82t 
625 ± 187t 
668 ± 203 
844 ± 202 
1023 ± 175 
377 ± 82t 
459 ± 113t 
646 ± 134t 
i Although there is a significant increase at 30 minutes of perfusion, 
this is not considered biologically significant because the fi~t 30 minutes 
of perfusion are considered an eq utlibr3tion period.42 
warm and cold ischemic injury and ultimately to prolon-
gation of organ preservation, will depend on a polyphar-
maceutic approach. 
Attempts to prevent or diminish ischemic injury as-
sociated with organ procurement and preservation have 
already involved the use of several pharmacologic agents. 
Prostacyclin has been used to enhance survival of canine 
livers preserved by hypothermic storage, and it has been 
shown to improve the survival of warm ischemically 
damaged liver allografts. 28 .29 Chlorpromazi ne has been 
found to prevent much of the calcium-mediated injury 
seen during reperfusion. 30.31 
There has been much interest recently in the role 
of oxygen-free radicals in ischemia and reperfusion in-
jury.I(}'14 Catalase. SOD, and allopurinol have been shown 
to protect against reperfusion injury mediated by oxygen-
free radicais. IO. 14 Other antioxidants and calcium channel 
blockers have also been used in an attempt to ameliorate 
ischemia/reperfusion injury.J2·34 Lidoflazine, a calcium 
channel blocker, has been shown to protect against re-
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perfusion injury during small bowel transplantation.J2 
Alpha-tocopherol has been demonstrated to prevent ox-
ygen-free radical damage in ischemic rat liver.J ) Marn-
bayashi et al. J4 have also used co-enzyme ubiquinone 
(QIO) to prevent ischemic hepatocyte damage. presum-
ably through the protection of membranes from lipid per-
oxidation, with preservation of calcium homeostasis and 
restoration of mitochondrial function. 
Platelet activating factor (PAf) has been proposed as 
a potential key inflammatory mediator of the microcir-
culatory failure that results after ischemic organ injury. 
PAF is released from several cells. including endothelial 
cells. platelets and neutrophils. and plays a significant role 
in almost every aspect of the basic inflammatory re-
sponse.8 In addhion to its effects on platelets. PAF induces 
neutrophil aggregation. activation. superoxide anion re-
lease. and acts directly on vascular endothelium to increase 
penneability. It also has smooth muscle contracting 
properties. 4 SRI 63-441 is one of the most potent PAF 
receptor antagonists developed to date.9 
A dose-dependent protective effect against warm isch-
emic/reperfusion injury was clearly demonstrated after 
donor pretreatment with SRI 63-441. Bile production. 
transaminase release. and A TP content all exhibited sig-
nificant improvement when compared with untreated 
ischemic controls in those livers from rats pretreated with 
FIGS. 6A-C. Low-magmficauon electron micrographs (stained with uranyl 
acetate and lead citrate. magmficauon X 1700). (A) Nonischemic control 
liver. Note intact endothelium (E) and normal appearing hcpatocytes 
(H). (B) IschemiC liver. ~ote nonviable hepalocytes (arrows). vacuoles 
(v). and relatively spared endothelium (E). (e) Ischemic liver from donors 
pretreated wllh SRI 63-441 (20 mg/kg). Note relauvely normal-appearing 
hepatocytes and intact endothelium (E) in this secllon. Light microscopy 
of larger surface areas did exhibit foci of vacuolization and nonviable 
hepatOC)1es. but to a lesser degree than in untreated ischemic livers. 
20 mg/kg of SRI 63-441 administered intravenously. 
When a lower dose of 10 mg/kg of SRI 63-441 was ad-
ministered. no significant improvement in liver function 
was demonstrated for any parameter measured when 
compared with ischemic controls. These results substan-
tiate the important role of PAF in ischemic organ injury, 
and moreover. introduces a potential therapeutic ap-
proach to organ ischemia and preservation through the 
inhibition of PAF by specific receptor antagonism. It is ; 
clear from the results reported here that prevention of: 
wann ischemic injury to the liver and improved hepatic:': 
function could be achieved by the administration of SRI 
63-441 as a pretreatment to liver donors. Because rat 
platelets are thOUght to be unresponsive to PAF,9 PAF-
mediated ischemic liver injury may be neutrophil-depen-
dent or. alternatively. may be due to some other PAF-
mediated pathway. The improved postiscbemic hepatic 
function demonstrated with SRI-63-44I pretreatment has 
c:ncouraging implications for liver preservation. especially 
because the same protective effect has been demonstrated 
for cold ischemic injury. J5 
SOD has been shown to have a protective effect on 
oxygen-free radical induced damage in kidneys subjected 
to wann ischemia and reperfusion. 13 During the period 
of ischemia. the foundation is laid for the reperfusion 
component of the injury. A TP is utilized and degraded 
'. !I'·01 tt' "k' KKKID~D ... 
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Fia. 7. Higher magnification 
electron micrograph of isch· 
emic liver (stained with ura· 
nyl acetate lead ci trate. mag· 
nification X 97(0). A non-
viable hepatocyte with 
disrupted mitochondria (M) 
and destruction of space of 
Disse (0) is seen adjacent to 
vacuolated (Cl but viable he· 
patocytes. Note that the en· 
dothelial cell (E) remains in 
dose contact ~ith the dam· 
aged but viable hepatocyte, 
but has pulled away from the 
nonviable hepatocyte. 
to hypoxanthine, and xanthine dehydrogenase is con-
vened to xanthine oxidase. At the time of reperfusion, 
oxygen·free radicals are generated.J6 The presence of SOD 
at the time of reperfusion can reduce the levels of super-
oxide anions. and hence, can reduce (at least theoretically) 
oxygen·free radical· mediated injury. The treatment 
grOUps in which SOD was added to the perfusate and was 
present at the time of reperfusion (Groups 6 and 8) ex-
hibited significant improvement in postischemic hepatic 
function. This was manifested as increased bile production 
(Group 6) and decreased transaminase liberation into the 
perfusate (Groups 6 and 8). The group in which SOD was 
not added to the perfusate during the reperfusion period 
(Group 8) did not show any significant improvement in 
hepatic function over ischemic controls. despite donor 
Pretreatment with SOD and the presence of SOD in the 
flUshing solution at the time of harvest (Table 3). The 
~tical moment of action for SOD is at the instant of 
reperfusion. Therefore, it is necessary that SOD be present 
In the perfusate at the time of reperfusion, as in Groups 
I} and 8. The livers in experimental Group 8 did exhibit 
decreased transaminase release, altbough bile production 
was not significantly improved when compared with non-
treated ischemic controls. This lack of improved bile pre> 
duction could possibly be a manifestation of SOD toxicity 
..... ' 
". ~~ ~K 
as the result of an increased total dosage of SOD resulting 
from the addition of SOD pretreatment to the protocol. 
Based on the improved postischemic function attained 
with SRI 63-441 (20 mg/kg) pretreatment and with the 
addition of SOD to the perfusate, a combined treatment 
protocol was evaluated for any synergistic effect. It was 
anticipated that the combination of two agents that acted 
via different mechanistic pathways might funher improve 
postischemic hepatic function. A lesser dose of SOD was 
added in the combination treatment study because initial 
experiments at the higher dosage did not show an increase 
in bile production and also because there was some con-
cern of toxicity. The addition of SOD to SRI 63-441 pre-
treatment did not result in an augmentation of the im-
provement already observed with SRI 63-441 pretreat-
ment alone. In fact, the results of the combined treatment 
group (Group 9) are somewhat equivocal. Although there 
was a significant increase in bile production and A TP 
content in the combined treatment group as compared 
to ischemic controls, there was no significant difference 
in transaminase release between the two groups. A po-
lypharmaceutic approach may indeed be required to 
achieve maximal pharmacologic modulation of ischemic/ 
reperfusion injury, because of the multiplicity and com-
plexity of the cascades involved, although such an ap-
I 
II I I 
I 
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proach may, in fact, "backfire" on occasion because of 
this very same complexity and incompletely understood 
interaction of these multiple pathways. The ultimate 
"cocktail" would contain several agents that act at differ-
ent critical points along the multiple pathways. Therefore 
it should also not be unexpected that. as with the com-
bined SRI 63-441 SOD treatment group, agents antici-
pated to behave synergistically could upset the fine balance 
in the cell's homeostatic mechanisms and invoke a det-
rimental response. 
The cyclooxygenase inhibitor, ibuprofen, has been im-
plicated as a beneficial agent in reducing ischemia/reper-
fusion injury to the brain, myocardium, and bowel. lS•11 
The ischemic livers treated with ibuprofen (Group 10) 
did not exhibit any significant improvement in postisch-
emic hepatic function by any of the parameters measured 
in this study. Cyc100xygenase is involved in the production 
of certain prostaglandins that would be beneficial in re-
ducing ischemia/reperfusion injury, as well as in the pro-
duction of thromboxanes and other prostaglandins that 
would be detrimental in ischemia/reperfusion injury.l?3. 
An overall inhibition of the activity of cyc100xygenase 
may. therefore. be too overwhelming a block in the cas-
cade and cancel out the beneficial effect of reducing 
thromboxane production. It may be that the addition of 
FIGs. 8A-C. Light micrographs (stained with PAS. magnification (X ~lK 
(AI Nonischemic control liver. Hepatocytes are darkly stained and aIy. 
cogen-Iaden. (B) Ischemic liver. There IS a patchy panem ofpaJe-stainina 
glycogen-depleted cells. (e) Ischemic liver from donors pretreated Witb 
SRI 63-441 (20 mg,lkg). The hepatocytes are pale-staining and glYtOlell-
depleted to a greater extent than in the ischemic livers, as represeuted 
in Figure 8B. 
prostacyclin to ibuprofen treatment may act synergistically 
and result in improved postischemic hepatic function. 
Because the group of animals pretreated with SRI 63-
41 (20 mg,lkg) exhibited the most marked improvement 
in postischemic hepatic function. electron microscopy was 
perfonned on these livers in order to ascertain any his- '.':. 
tolegic improvement in organ status. Ischemic pretreated ~ 
livers (Group 4) were compared with ischemic (Group OF:D::D~ 
and nonischemic (Group I) controls, whicb were p~ 
cessed in an identical fashion. . 
The morphologic appearance of the nonischemic con~ . 
trollivers was that of nonnal liver without any evidence 
of hepatocellular or endothelial injury, indicating that 
changes in the experimental groups are not artifactual. 
The general pattern of injury observed in the iscbemic 
livers and the ischemic livers harvested from donors pre-
treated with SRI 63-441 (20m g,Ikg) was almost identical 
in nature and consisted of patchy hepatocellular vacuoli-
zation and nonviable hepatocytes interspersed with viable 
cells. However, the degree of injury appeared less severe 
in the group pretreated with SRI 63-441 (Group 4); the 
foci of damage were smaller and less abundant than iD 
the untreated ischemic group (Group 2). The vacuoliza-
tion observed is characteristic of hypoxic injury.l9.40 
The sinusoidal endothelium was relatively spared even 
• wen 
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in the most severely damaged warm ischemic livers. This 
is of singular importance because the primary abnormality 
seen in livers after cold ischemic or preservation injury is 
endothelial disruption. 1.35 Sinusoidal endothelial injury is 
apparent in livers injured by cold ischemia while still 
manifesting nonnal hepatocellular architecture. Hepa-
tocellular injury manifested by vacuolization does not oc-
cur until prolongation of cold ischemic injury well past 
the point where endothelial injury becomes apparent.35 
This difference in morphology after warm and cold isch-
emia has only recently been appreciated and lends further 
credence to the belief that warm and cold ischemia rep-
resent two different and distinct types of injury.' More-
over, it should become possible to use these different and 
specific pathologic changes as predictors of organ function. 
The glycogen depletion observed in those livers pre-
treated with SRI 63-441 (Groups 3 and 4) was at first 
puzzling because it would be expected that the more 
"healthy," better-functioning livers would retain their 
glycogen. However, in addition to its role in the inflam-
matory response. PAF has a potent agonist effect on the 
glycogenolytic system in the rat liver.4' It is possible that 
SRI 63-441, the structurally similar PAF receptor antag-
onist, may have the same action as PAF itself on the gly-
cogenolytic system activate glycogenolysis. 
In summary, the platelet activating factor antagonist, 
SRI 63-441, significantly reduced hepatic wann ischemic 
injury in a dose-dependent fashion, thereby substantiating 
the role of PAF in ischemic organ injury and introducing 
a novel therapeutic approach. The oxygen-free radical 
scavenger, SOD, exerted a protective effect on postisch-
emic hepatic function only if present at the exact time of 
reperfusion (and of generation of free radicals). The cy-
clooxygenase inhibitor, ibuprofen, was ineffective in pro-
tecting the liver from wann ischemic injury under the 
conditions represented by these experiments. The mor-
phologic findings in this study reveal a pattern of hepatic 
injury involving primarily parenchymal cells after wann 
ischemia that differs significantly from the primarily en-
dothelial injury seen subsequent to cold ischemia. 1.35 Liver 
allografts undergo periods of both warm and cold ischemia 
during the transplantation process. Therefore, pharma-
cologic amelioration of ischemic injury with prolongation 
of Organ preservation will involve the administration of 
agents, singly or in well-defined combinations. which will 
not only protect against parenchymal cellular injury and 
disruption, but will also maintain the endothelial integrity 
of the organ. 
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